SARS-CoV-2 has transformed the lives of Americans and rapidly changed the delivery of healthcare. Initial reports suggested that children and adolescents were largely spared from developing COVID-19 despite being positive for SARS-CoV-2; however, recent reports from our center found that the disease has a different trajectory in children as many have developed multisystem inflammatory disorder (MIS- C). We still have much to learn about SARS-CoV-2. An initial first step is understanding seroconversion and the clinical, biological, and sociodemographic characteristics that may either promote or prevent seroconversion in a highly vulnerable pediatric group of patients. It has been established that the immunosuppression associated with cancer therapy limits both humoral and cellular immune responses; however, the specificity and function of antibodies vs. SARS-CoV-2 that may be generated in these children, and their correlation to recovery, are unknown. Our preliminary data suggests that immunocompromised children undergoing treatment for cancer may develop a detectable immune response to SARS-CoV-2, but the duration of the presence of antibodies and their associated neutralizing activities are unknown. To best manage children with cancer, it is essential to understand how seroconversion correlates with recovery from immunosuppression, how long protection lasts, and whether the antibody response is protective against SARS-CoV-2. We propose an observational cohort study recruiting 120 children and adolescents undergoing treatment for cancer at the Columbia University Irving Medical Center. At a routine clinical visit, participants will be recruited for a 6- week period in which we will perform a nasal swab to determine positivity to SARS-CoV-2, collect blood (antibody detection and neutralizing activity) and stool (metagenomics sequencing of the microbiome) specimens at 3- and 6-weeks post study entry. At the same time, we will interview participants? parents collecting information on sociodemographic factors associated with viral exposure. We will investigate the presence and activity of antibodies for SARS-CoV-2, controlling for the duration and severity of immunosuppression and explore if socio demographic characteristics that facilitate exposure to SARS-CoV-2 are associated with seroconversion. The long-term impact of our proposed research may result in new strategies in prevention techniques and screening modalities that may be implemented in subsequent waves of the virus.

Public Health Relevance

There is much to learn about SARS-CoV-2 and childhood cancer. An initial step is to understand seroconversion and the clinical, biological, and sociodemographic characteristics associated with the presence of antibodies, duration of antibodies, and their associated neutralizing activity in a group of highly immunosuppressed children with cancer. This will aid investigators in identifying risk factors that promote or hinder children's ability to seroconvert while undergoing treatment for cancer.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
3P30CA013696-45S3
Application #
10203274
Study Section
Subcommittee I - Transistion to Independence (NCI)
Program Officer
Belin, Precilla L
Project Start
1997-07-04
Project End
2025-06-30
Budget Start
2020-08-21
Budget End
2021-06-30
Support Year
45
Fiscal Year
2020
Total Cost
Indirect Cost
Name
Columbia University (N.Y.)
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
621889815
City
New York
State
NY
Country
United States
Zip Code
10032
Ghorpade, Devram S; Ozcan, Lale; Zheng, Ze et al. (2018) Hepatocyte-secreted DPP4 in obesity promotes adipose inflammation and insulin resistance. Nature 555:673-677
Jauregui, Ruben; Thomas, Amanda L; Liechty, Benjamin et al. (2018) SCAPER-associated nonsyndromic autosomal recessive retinitis pigmentosa. Am J Med Genet A :
Jauregui, Ruben; Park, Karen Sophia; Duong, Jimmy K et al. (2018) Quantitative Comparison of Near-infrared Versus Short-wave Autofluorescence Imaging in Monitoring Progression of Retinitis Pigmentosa. Am J Ophthalmol 194:120-125
Bianchetti, E; Bates, S J; Carroll, S L et al. (2018) Usp9X Regulates Cell Death in Malignant Peripheral Nerve Sheath Tumors. Sci Rep 8:17390
Shang, Enyuan; Zhang, Yiru; Shu, Chang et al. (2018) Dual Inhibition of Bcl-2/Bcl-xL and XPO1 is synthetically lethal in glioblastoma model systems. Sci Rep 8:15383
Proto, Jonathan D; Doran, Amanda C; Subramanian, Manikandan et al. (2018) Hypercholesterolemia induces T cell expansion in humanized immune mice. J Clin Invest 128:2370-2375
Apatoff, Mary Ben L; Sengillo, Jesse D; White, Eugenia C et al. (2018) Autologous stem cell therapy for inherited and acquired retinal disease. Regen Med 13:89-96
Shen, Megan Johnson; Prigerson, Holly G; Ratshikana-Moloko, Mpho et al. (2018) Illness Understanding and End-of-Life Care Communication and Preferences for Patients With Advanced Cancer in South Africa. J Glob Oncol :1-9
Connors, Thomas J; Baird, J Scott; Yopes, Margot C et al. (2018) Developmental Regulation of Effector and Resident Memory T Cell Generation during Pediatric Viral Respiratory Tract Infection. J Immunol 201:432-439
Billing, David; Horiguchi, Michiko; Wu-Baer, Foon et al. (2018) The BRCT Domains of the BRCA1 and BARD1 Tumor Suppressors Differentially Regulate Homology-Directed Repair and Stalled Fork Protection. Mol Cell 72:127-139.e8

Showing the most recent 10 out of 331 publications